Develops diagnostic products that improve patient outcomes and reduce the cost of healthcare.
T2 Biosystems, Inc. is a leading in vitro diagnostics company dedicated to advancing diagnostic solutions both domestically and globally. Leveraging innovative technology, the company specializes in developing products and candidates that detect pathogens, biomarkers, and various abnormalities directly from unpurified patient samples such as whole blood, plasma, serum, and saliva. This capability is crucial for rapid and accurate diagnosis across a range of medical conditions.
At the heart of T2 Biosystems offerings is the T2Dx Instrument, a versatile bench-top device capable of running a variety of diagnostic tests from patient samples. Key products include T2Candida and T2Bacteria, direct-from-blood tests that identify pathogens responsible for bloodstream infections like sepsis and candidemia. The company also provides T2Resistance for detecting carbapenem resistance genes and the T2SARS-CoV-2 panel designed to detect the SARS-CoV-2 virus, underscoring its commitment to addressing critical healthcare challenges.
In addition to its current portfolio, T2 Biosystems is actively developing new diagnostic solutions. These include T2Biothreat for detecting biothreat pathogens, a comprehensive sepsis panel to identify antibiotic-resistant markers, T2Cauris for detecting Candida auris, and T2Lyme for identifying Lyme disease-causing bacteria directly from blood samples. With strategic collaborations in place, such as with Canon U.S. Life Sciences, Inc. for Lyme disease detection, T2 Biosystems continues to expand its impact in diagnostic innovation. Established in 2006 and headquartered in Lexington, Massachusetts, the company remains dedicated to improving patient outcomes through cutting-edge diagnostic technologies.